Synergistic bacterial compositions and methods of production and use thereof
Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.
1. A method of treating or preventing recurrence of Clostridium difficile ( C. difficile ) infection in a subject in need thereof, comprising administering to the subject a composition comprising a first species of isolated bacterium and a second species of isolated bacterium, wherein the first species is Clostridium innocuum and the second species is Clostridium orbiscindens , wherein the Clostridium orbiscindens comprises a 16S rDNA sequence that is at least 97% identical to SEQ ID NO: 548.
2. The method of claim 1 , wherein the first species and the second species are capable of inhibiting C. difficile growth as measured by a CivSim assay.
3. The method of claim 2 , wherein the first species and the second species are capable of inhibiting C. difficile growth in a CivSim assay with a confidence interval of >99% (++++).
4. The method of claim 1 , wherein the first species, the second species, or both are capable of forming a spore.
5. The method of claim 1 , wherein the first species, the second species, or both are in the form of spores.
6. The method of claim 1 , wherein the composition is formulated for populating the gastrointestinal tract of the subject.
7. The method of claim 1 , wherein the first species, the second species, or both are lyophilized.
8. The method of claim 1 , wherein the Clostridium orbiscindens comprises a 16S rDNA sequence that is at least 98% identical to SEQ ID NO: 548.
9. The method of claim 1 , wherein the Clostridium orbiscindens comprises a 16S rDNA sequence that is at least 99% identical to SEQ ID NO: 548.
10. The method of claim 1 , wherein the Clostridium orbiscindens comprises the 16S rDNA sequence set forth in SEQ ID NO: 548.
11. The method of claim 1 , wherein the Clostridium innocuum comprises a 16S rDNA sequence that is at least 97% identical to SEQ ID NO: 534.
12. The method of claim 1 , wherein the Clostridium innocuum comprises a 16S rDNA sequence that is at least 98% identical to SEQ ID NO: 534.
13. The method of claim 1 , wherein the Clostridium innocuum comprises a 16S rDNA sequence that is at least 99% identical to SEQ ID NO: 534.
14. The method of claim 1 , wherein the Clostridium innocuum comprises the 16S rDNA sequence set forth in SEQ ID NO: 534.
15. The method of claim 1 , wherein the composition is formulated for oral administration.
16. The method of claim 1 , wherein the composition further comprises an enteric coating.
17. A method of treating a dysbiosis in a subject in need thereof, comprising administering to the subject a composition comprising a first species of isolated bacterium and a second species of isolated bacterium, wherein the first species is Clostridium innocuum and the second species is Clostridium orbiscindens , wherein the Clostridium orbiscindens comprises a 16S rDNA sequence that is at least 97% identical to SEQ ID NO: 548.
18. A method of producing a bacterial composition, comprising combining a first species of isolated bacterium and a second species of isolated bacterium, wherein the first species is Clostridium innocuum and the second species is Clostridium orbiscindens , wherein the Clostridium orbiscindens comprises a 16S rDNA sequence that is at least 97% identical to SEQ ID NO: 548.